Research and Markets has announced the addition of the "Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2016" report to their offering.
Deep Vein Thrombosis (DVT) pipeline therapeutics constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Deep Vein Thrombosis (DVT), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The molecules developed by Companies in Pre-Registration, Phase I and Preclinical stages are 4, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Deep Vein Thrombosis (DVT) and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/2t7nl9/deep_vein
View source version on businesswire.com: http://www.businesswire.com/news/home/20161027006229/en/Business Wire
Last updated on: 27/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.